New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

3b5b149a-05ee-4d16-bcb4-596e35dd3d5darticleimage.jpg

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Atopic Dermatitis (AD) is an inflammatory skin disease that affects 20 percent of children worldwide. It’s the most common form of eczema and typically involves symptoms such as redness, dry skin and an intense itch.

The disease of AD can significantly reduce the quality of life for patients and their families. Furthermore, children suffering from AD have an increased risk of other atopic disorders, including asthma, allergic rhinitis and chronic sinusitis. Steroids are the most commonly prescribed medication for the treatment of AD and often have undesirable side effects.

Benefits of probiotics mix
The research was conducted by Dr. Vicente Navarro-López and coworkers and involved 50 AD patients aged 4 to 17. The study involved a probiotic mixture in the form of a bulk powder that was made from three different Biopolis proprietary culture strains.

The culture mix was provided to the patients as a supplement, in capsule form, taken orally. It was designed so that the probiotics were administered together with topical corticosteroids, given the supplementary nature of the probiotic treatment. The study was randomized, double blinded and placebo controlled.

In summarizing the outcomes of the 12-week study, the researchers stated: “The mixture of probiotics was effective in reducing SCORAD (Scoring Atopic Dermatitis) index and reducing the use of topical steroids in patients with moderate AD.”

“These results illustrate the tremendous potential of probiotics used in this study to really make a difference to the quality of life for these young AD patients,” says Daniel Ramón Vidal, VP R&D, ADM Bioactives. “This study was directed at children with moderate Atopic dermatitis, and given the success and positive results we’ve seen, we are now planning future studies amongst children with both mild and severe Atopic dermatitis, as well as in adults with similar symptoms to continue to evaluate the potential of this mixture.”

The potential of probiotics to treat allergies was also recently reinforced by a study suggesting that modifying the gut microbiome may eventually prevent asthma in infant boys. The wider benefits of a healthy microbiome were also suggested by study results showing that the “ridiculously healthy” had the same microbiome as healthy 30-year-olds. 

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Key gut-brain interplays identified, enhancing possibilities for neurological treatments

21 May 2018 --- Steps have been taken toward untangling the complex interplay that allows the byproducts of microorganisms living in the gut to influence the progression of neurodegenerative diseases. Researchers have defined a pathway between the two, coined the gut-brain axis, that may help guide therapies for multiple sclerosis and other neurological diseases. Essentially, some gut microbes were found to activate an anti-inflammatory pathway that can limit neurodegeneration.

Nutrition & Health News

Sports nutrition mainstreams: A key theme at Vitafoods Europe 2018

18 May 2018 --- Boundaries are blurring as sports nutrition continues to move mainstream. Ingredients and products aimed at promoting active living were a clear standout theme at Vitafoods Europe this year. New launches targeted a wide scope of aspects related to active lifestyles, and are likely to resonate not just with hardcore athletes but also with consumers of different ages and activity groups. 

Nutrition & Health News

Protein provides benefit for adult bone and joint health, expert consensus reports

17 May 2018 --- Dietary protein intake above the recommended levels may help reduce bone loss and fracture risk in seniors with osteoporosis, an expert consensus reports. Based on an analysis of major research studies, the review, published in Osteoporosis International, found that a protein-rich diet is beneficial for adult bone health. The consensus debunks the popular myth that too much protein may be damaging to bone health.

Nutrition & Health News

“Key milestone”: Chr. Hansen trial finds probiotic potential for painkiller gut damage defense

16 May 2018 --- A Chr. Hansen clinical trial has demonstrated the effectiveness of probiotic strains in protecting against potential gut damage caused by the regular use of household painkillers. Chr. Hansen state that they will now focus on fully exploiting the strains full potential, deepening understanding of the underlying mechanisms and gathering sufficient data to publish in a scientific journal. The findings add to a growing research area using probiotics for health.

Nutrition & Health News

Kaneka takes stake in AB-Biotics, aims for major boost in probiotic sales by 2022

14 May 2018 --- Japanese specialty chemical company Kaneka Corporation has acquired 34.8 percent of Spanish owned AB-Biotics (ABB) who focus on the research, development and distribution of lactic acid bacteria products. The agreement also grants Kaneka the exclusive rights for production and sales of ABB’s products in the US, Canada and Japan. The company hopes to accomplish 10 billion yen (US$91 million) in sales by 2022, by developing and launching differentiated new probiotic products in the fast-growing market.

More Articles
URL : http://www.nutritioninsight.com:80/news/new-biopolis-probiotic-mix-helps-reduce-topical-steroid-use-by-atopic-dermatitis-patients.html